Sun Young RHA
Yonsei University Health System,
Sun Young Rha, MD, PhD, is an Associate Professor and currently the Chief of Medical Oncology in the Department of Internal Medicine at the Yonsei University College of Medicine, Seoul, South Korea. She is also the Chief of the Division of Genomics and Translational Research, Cancer Metastasis Research Center, Yonsei University, and the Director of Human Research Protection Center, Severance Hospital, Yonsei University Health System.
Professor Rha is a medical oncologist and clinical and translational researcher, mainly in the areas of gastric cancer, renal cell carcinoma, and sarcoma. Her research interests include therapeutic strategies and new drug development, genomics-based biomarker development, pharmacogenomics/pharmacogenetics, angiogenesis and metastasis. As a clinical researcher she has been involved in various clinical trials of phase I through III, and worked as a main principal investigator for the Korean Cancer Study Group. She is also a translational researcher involved in preclinical anticancer drug screening with potential mechanism evaluation and in several correlative studies for biomarker development.
Currently professor Rha is a chair of the GU/GY Committee and a member of gastric cancer committee of the Korean Cancer Study Group. She is also a key member of the Cancer Therapeutics Research Group, Asia-Pacific collaborative clinical research cooperative group, and the National Comprehensive Cancer Network Asia Consensus Statement Panel for Kidney Cancer.
Abstract Title: Pharmocogenomic biomarker in cancer treatment
Regardless of advances in the treatment method, the various treatment efficacy and toxicities due to tumor heterogeneity are the major obstacles in cancer treatment. In addition to the clinical variables such as age, gender, organ function and tumor types, the genetic differences of the tumor tissues and the host play a significant role in diverse efficacy and toxicity to chemotherapeutic agents. As the biology and genomics are improved, the treatment based on the predictive pharmacogenomics, the genome-wide evaluation of potential biomarkers for predicting treatment efficacy and toxicity, becomes one of the significant approaches for the personalized therapy, resulting in maximizing the efficacy and minimizing the toxicity of each patient. Microarray technology, one of the major technologies in post-genome area, allows us to screen thousands of genes without a priori knowledge. Moreover, we can identify a panel of genes which are more informative in combination for various clinical outcomes. Here, I will share several approaches of pharmacogenomics in gastric cancer for identifying predictive biomarker and therapeutic targets in gastric cancer as a basis for the individualized therapy.
|Back to Speakers|